Annual Total Liabilities
$68.61 M
-$29.19 M-29.84%
December 31, 2024
Summary
- As of March 9, 2025, SLN annual total liabilities is $68.61 million, with the most recent change of -$29.19 million (-29.84%) on December 31, 2024.
- During the last 3 years, SLN annual total liabilities has fallen by -$49.71 million (-42.01%).
- SLN annual total liabilities is now -42.01% below its all-time high of $118.32 million, reached on December 31, 2021.
Performance
SLN Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$68.61 M
-$31.58 M-31.52%
December 1, 2024
Summary
- As of March 9, 2025, SLN quarterly total liabilities is $68.61 million, with the most recent change of -$31.58 million (-31.52%) on December 1, 2024.
- Over the past year, SLN quarterly total liabilities has dropped by -$27.68 million (-28.74%).
- SLN quarterly total liabilities is now -42.01% below its all-time high of $118.32 million, reached on December 31, 2021.
Performance
SLN Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
SLN Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -29.8% | -28.7% |
| 3 y3 years | -42.0% | -28.7% |
| 5 y5 years | +107.9% | -28.7% |
SLN Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.0% | at low | -42.0% | at low |
| 5 y | 5-year | -42.0% | +107.9% | -42.0% | +107.9% |
| alltime | all time | -42.0% | >+9999.0% | -42.0% | +4937.2% |
Silence Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $68.61 M(-29.8%) | - |
| Dec 2024 | - | $68.61 M(-31.5%) |
| Sep 2024 | - | $100.19 M(+4.1%) |
| Jun 2024 | - | $96.29 M(+8.2%) |
| Mar 2024 | - | $88.98 M(-9.0%) |
| Dec 2023 | $97.80 M(-5.4%) | $97.80 M(+2.8%) |
| Sep 2023 | - | $95.10 M(-6.3%) |
| Jun 2023 | - | $101.48 M(+5.4%) |
| Mar 2023 | - | $96.29 M(-6.9%) |
| Dec 2022 | $103.38 M(-12.6%) | $103.38 M(+3.0%) |
| Sep 2022 | - | $100.40 M(-6.1%) |
| Jun 2022 | - | $106.91 M(-1.7%) |
| Mar 2022 | - | $108.76 M(-8.1%) |
| Dec 2021 | $118.32 M(+12.9%) | $118.32 M(+15.3%) |
| Sep 2021 | - | $102.58 M(-3.8%) |
| Jun 2021 | - | $106.65 M(+1.7%) |
| Dec 2020 | $104.82 M(+217.6%) | $104.82 M(+17.5%) |
| Jun 2020 | - | $89.19 M(+170.3%) |
| Dec 2019 | $33.00 M(+579.0%) | - |
| Dec 2019 | - | $33.00 M(+810.8%) |
| Jun 2019 | - | $3.62 M(-25.4%) |
| Dec 2018 | $4.86 M(+35.3%) | - |
| Dec 2018 | - | $4.86 M(+3.2%) |
| Jun 2018 | - | $4.71 M(+31.2%) |
| Dec 2017 | $3.59 M(+80.8%) | - |
| Dec 2017 | - | $3.59 M(-0.3%) |
| Jun 2017 | - | $3.60 M(+81.3%) |
| Dec 2016 | $1.99 M(+19.9%) | - |
| Dec 2016 | - | $1.99 M(-2.1%) |
| Jun 2016 | - | $2.03 M(+22.5%) |
| Dec 2015 | $1.66 M(-47.1%) | - |
| Dec 2015 | - | $1.66 M(+13.7%) |
| Jun 2015 | - | $1.46 M(-53.5%) |
| Dec 2014 | $3.13 M(+10.2%) | - |
| Dec 2014 | - | $3.13 M(+20.5%) |
| Jun 2014 | - | $2.60 M(-8.5%) |
| Dec 2013 | $2.84 M | - |
| Dec 2013 | - | $2.84 M(+100.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $1.42 M(-8.7%) |
| Dec 2012 | $1.55 M(-20.8%) | - |
| Dec 2012 | - | $1.55 M(+0.6%) |
| Jun 2012 | - | $1.54 M(-21.2%) |
| Dec 2011 | $1.96 M(-24.8%) | - |
| Dec 2011 | - | $1.96 M(-41.3%) |
| Jun 2011 | - | $3.33 M(+28.0%) |
| Dec 2010 | $2.60 M(-23.5%) | - |
| Dec 2010 | - | $2.60 M(-37.1%) |
| Jun 2010 | - | $4.14 M(+21.7%) |
| Dec 2009 | $3.40 M(+148.4%) | - |
| Dec 2009 | - | $3.40 M(+149.7%) |
| Jun 2009 | - | $1.36 M(-0.5%) |
| Dec 2008 | $1.37 M(-61.7%) | - |
| Dec 2008 | - | $1.37 M(-12.5%) |
| Jun 2008 | - | $1.56 M(-56.2%) |
| Dec 2007 | $3.57 M(+74.7%) | - |
| Dec 2007 | - | $3.57 M(-7.8%) |
| Jun 2007 | - | $3.87 M(+89.4%) |
| Dec 2006 | $2.05 M(-20.0%) | - |
| Dec 2006 | - | $2.05 M(+23.0%) |
| Jun 2006 | - | $1.66 M(-34.9%) |
| Dec 2005 | $2.56 M(+57.5%) | - |
| Dec 2005 | - | $2.56 M(+51.3%) |
| Jun 2005 | - | $1.69 M(+4.1%) |
| Dec 2004 | $1.62 M(-30.4%) | - |
| Dec 2004 | - | $1.62 M(+8.9%) |
| Jun 2004 | - | $1.49 M(-36.1%) |
| Dec 2003 | $2.33 M(+40.8%) | - |
| Dec 2003 | - | $2.33 M(+22.9%) |
| Jun 2003 | - | $1.90 M |
| Dec 2002 | $1.66 M(+57.2%) | - |
| Dec 2001 | $1.05 M(-26.8%) | - |
| Dec 2000 | $1.44 M(-44.5%) | - |
| Dec 1999 | $2.59 M(+159.1%) | - |
| Dec 1998 | $1.00 M(-5.4%) | - |
| Dec 1997 | $1.06 M(+48.2%) | - |
| Dec 1996 | $714.10 K(+53.5%) | - |
| Dec 1995 | $465.10 K | - |
FAQ
- What is Silence Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Silence Therapeutics?
- What is Silence Therapeutics annual total liabilities year-on-year change?
- What is Silence Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Silence Therapeutics?
- What is Silence Therapeutics quarterly total liabilities year-on-year change?
What is Silence Therapeutics annual total liabilities?
The current annual total liabilities of SLN is $68.61 M
What is the all time high annual total liabilities for Silence Therapeutics?
Silence Therapeutics all-time high annual total liabilities is $118.32 M
What is Silence Therapeutics annual total liabilities year-on-year change?
Over the past year, SLN annual total liabilities has changed by -$29.19 M (-29.84%)
What is Silence Therapeutics quarterly total liabilities?
The current quarterly total liabilities of SLN is $68.61 M
What is the all time high quarterly total liabilities for Silence Therapeutics?
Silence Therapeutics all-time high quarterly total liabilities is $118.32 M
What is Silence Therapeutics quarterly total liabilities year-on-year change?
Over the past year, SLN quarterly total liabilities has changed by -$27.68 M (-28.74%)